These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21674877)

  • 1. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
    Sahin I; Ararat E; Altundag K
    J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP inhibition in BRCA-mutated breast and ovarian cancers.
    Chan SL; Mok T
    Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
    [No Abstract]   [Full Text] [Related]  

  • 3. [Olaparib in ovarian cancer with BRCA mutation].
    Pujade-Lauraine É; Combe P
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib effective in four advanced cancers.
    Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PARP inhibitors to treat triple negative breast cancer].
    Sugie T
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2850-5. PubMed ID: 21235091
    [No Abstract]   [Full Text] [Related]  

  • 8. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
    Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib for the treatment of breast cancer.
    Robert M; Frenel JS; Gourmelon C; Patsouris A; Augereau P; Campone M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):751-759. PubMed ID: 28395540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
    Gartner EM; Burger AM; Lorusso PM
    Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    Chen Y; Zhang L; Hao Q
    Arch Gynecol Obstet; 2013 Aug; 288(2):367-74. PubMed ID: 23619942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
    Roviello G; Milani M; Gobbi A; Dester M; Cappelletti MR; Allevi G; Aguggini S; Ravelli A; Gussago F; Cocconi A; Zanotti L; Senti C; Strina C; Bottini A; Generali D
    Future Oncol; 2016 Oct; 12(19):2189-93. PubMed ID: 27324108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib for the treatment of breast cancer.
    Griguolo G; Dieci MV; Guarneri V; Conte P
    Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 17. Response of
    Xie Y; Jiang Y; Yang XB; Wang AQ; Zheng YC; Wan XS; Sang XT; Wang K; Zhang DD; Xu JJ; Li FG; Zhao HT
    World J Gastroenterol; 2016 Dec; 22(46):10254-10259. PubMed ID: 28028375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
    Venkitaraman AR
    Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
    Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.